Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.85 |
| ▸ | ALPI | P09923 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | XIAP | P98170 | 1/20 | 0.85 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 2/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPA3 | P15088 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL1637917 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL4862934 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL1011892 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL1537448 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL3496164 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL2679075 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL9650016 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL218898 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL21816915 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL27579186 | 1.00 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102670428-A | Preparation method and applications for cyclodextrin collagen tripeptide inclusion complex water solution | UNIV FUDAN | 2012-09-19 | — | — | CN | claimed |
| EP-0173233-B1 | CHROMATOGRAPHIC METHOD AND MEANS | PURDUE RESEARCH FOUNDATION (US) | 1989-01-18 | — | — | EP | claimed |
| EP-0173233-A2 | Chromatographic method and means | PURDUE RESEARCH FOUNDATION (US) | 1986-03-05 | — | — | EP | claimed |
| US-4544485-A | HYDROPHOBIC COATING ON INNER SURFACES, HYDROPHILIC COATINGS ON OUTER SURFACES; SMALL PORE SIZE | PURDUE RESEARCH FOUNDATION (US) | 1985-10-01 | — | — | US | claimed |
| US-4340592-A | OLICOPEPTIDES FOR DIETARY PURPOSES | ADIBI SIAMAK A | 1982-07-20 | — | — | US | claimed |
| US-20230014151-A1 | COMBINATION ANTIVIRAL THERAPY FOR MEASLES | CORNELL UNIVERSITY | 2023-01-19 | — | — | US | disclosed |
| EP-4025586-A2 | COMBINATION ANTIVIRAL THERAPY FOR MEASLES | The Trustees of Columbia University in the City of New York (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021046398-A2 | COMBINATION ANTIVIRAL THERAPY FOR MEASLES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-03-11 | — | — | WO | disclosed |
| CN-107811996-A | New type water-solubility tanshinone IIA polypeptide hydrogel nanometer medicine-carried system | 中国药科大学 | 2018-03-20 | — | — | CN | disclosed |
| CN-107488209-A | Gelator and its hydrogel prepare and application | 四川大学 | 2017-12-19 | — | — | CN | disclosed |
| US-9006170-B2 | Compositions for elastogenesis and connective tissue treatment | HUMAN MATRIX SCIENCES, LLC (US) | 2015-04-14 | — | — | US | disclosed |
| US-8871707-B2 | Elastin producing fibroblast formulations and methods of using the same | HUMAN MATRIX SCIENCES, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2004037848-A2 | PROCESS FOR DETERMINING TARGET FUNCTION AND IDENTIFYING DRUG LEADS | SLANETZ ALFRED E (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1344060-A2 | PROCESS FOR DETERMINING TARGET FUNCTION AND IDENTIFYING DRUG LEADS | Slanetz, Alfred E. (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002058533-A2 | PROCESS FOR DETERMINING TARGET FUNCTION AND IDENTIFYING DRUG LEADS | SLANETZ ALFRED E (US) | 2002-08-01 | — | — | WO | disclosed |
| US-20020046966-A1 | Use of support materials in capillary electrochromatography | EVOTEC BIOSYSTEMS AG (DE) | 2002-04-25 | — | — | US | disclosed |
| US-5164090-A | Separation of hydrophobic material, glass beads, controlled pore size | E. R. SQUIBB & SONS, INC. (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0173233-B1 | CHROMATOGRAPHIC METHOD AND MEANS | PURDUE RESEARCH FOUNDATION (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0173233-A2 | Chromatographic method and means | PURDUE RESEARCH FOUNDATION (US) | 1986-03-05 | — | — | EP | disclosed |
| US-4544485-A | HYDROPHOBIC COATING ON INNER SURFACES, HYDROPHILIC COATINGS ON OUTER SURFACES; SMALL PORE SIZE | PURDUE RESEARCH FOUNDATION (US) | 1985-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014151-A1 | COMBINATION ANTIVIRAL THERAPY FOR MEASLES | HM13, LRPPRC, TFRC | ADORA3 4161/4885SLC7A5 2450/4885PTGS1 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.